Literature DB >> 1711442

Cardiovascular therapies in the 1990s. An overview.

R C Becker1, J M Gore.   

Abstract

Cardiovascular medicine has evolved steadily over the past two decades. Inspired by progressive declines in the overall incidence and mortality rates from cardiovascular diseases, emphasis has been placed on 3 specific areas: prevention, early diagnosis, and aggressive intervention. During the decade spanning the 1980s, impressive strides were made in many areas--diagnostic and therapeutic alike. However, an observed reduction in patient mortality stemming from acute myocardial infarction was particularly gratifying. Clearly, the large scale use of thrombolytic therapy and postinfarction strategies designed to prevent reinfarction, limit ventricular dilation, and reduce cardiac death figured prominently. Despite these encouraging facts, however, coronary heart disease remains the leading cause of death in Western society, and thrombolytic therapy is still not being utilised by the medical community to its full potential. Furthermore, adjuvant therapy, during both the early and the late phases of acute myocardial infarction, is being instituted inconsistently, and at times haphazardly. Arrhythmia management and the prevention of sudden cardiac death require further investigation, as does the treatment of chronic congestive heart failure, and the prevention of coronary atherosclerosis. This overview provides a state-of-the-art review and look into the future of 5 critical areas: acute myocardial infarction, adjuvant treatment strategies for acute myocardial infarction, cardiac arrhythmias, chronic congestive heart failure, and hyperlipidaemias.

Entities:  

Mesh:

Year:  1991        PMID: 1711442     DOI: 10.2165/00003495-199141030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  117 in total

1.  A symposium: Pharmacological management of ventricular arrhythmias--current status in the role of moricizine HCl. October 19-22, 1989, Scottsdale, Arizona. Proceedings.

Authors: 
Journal:  Am J Cardiol       Date:  1990-02-20       Impact factor: 2.778

2.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

3.  Antibody-enhanced thrombolysis: capture of tissue plasminogen activator by a bispecific antibody and direct targeting by an antifibrin-tissue plasminogen activator conjugate in vivo.

Authors:  M S Runge; C Bode; G R Matsueda; E Haber
Journal:  Trans Assoc Am Physicians       Date:  1987

Review 4.  Drug therapy: atenolol and timolol, two new systemic beta-adrenoceptor antagonists.

Authors:  W H Frishman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

5.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

6.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

7.  Intracoronary thrombolysis with an acylated streptokinase-plasminogen activator (BRL 26921) in patients with acute myocardial infarction.

Authors:  W Kasper; R Erbel; T Meinertz; M Drexler; A Rückel; T Pop; W Prellwitz; J Meyer
Journal:  J Am Coll Cardiol       Date:  1984-08       Impact factor: 24.094

8.  Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias.

Authors:  J P diMarco; T D Sellers; B B Lerman; M L Greenberg; R M Berne; L Belardinelli
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

9.  Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.

Authors:  S I Rajfer; J D Rossen; F L Douglas; L I Goldberg; T Karrison
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

10.  Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.

Authors: 
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

View more
  1 in total

Review 1.  Cardiovascular drugs.

Authors:  P Vermeij
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.